Coronary Artery Bypass Graft Market Report 2026

The coronary artery bypass graft market size has grown strongly in recent years. It will grow from $13.61 billion in 2025 to $14.82 billion in 2026 at a compound annual growth rate (CAGR) of 8.9%. The growth in the historic period can be attributed to high coronary artery disease prevalence, limited alternative revascularization options, aging population growth, hospital-based surgical dominance, improved survival rates.

The coronary artery bypass graft market size is expected to see strong growth in the next few years. It will grow to $21.08 billion in 2030 at a compound annual growth rate (CAGR) of 9.2%. The growth in the forecast period can be attributed to advancements in surgical techniques, growing cardiac surgery volumes, improved patient outcomes, expansion of cardiac specialty centers, increasing healthcare expenditure. Major trends in the forecast period include growing adoption of minimally invasive cabg, increased use of off-pump procedures, rising demand for multi-vessel bypass surgeries, improved post-surgical recovery protocols, expansion of hybrid cardiac procedures.

The rising prevalence of cardiovascular diseases is expected to support the growth of the coronary artery bypass graft market in the coming years. Cardiovascular disease (CVD) broadly includes a wide range of conditions affecting the heart and blood vessels. Coronary artery bypass graft (CABG) surgery is commonly recommended to lower the risk of heart attacks by creating an alternative route for blood flow around blocked or partially obstructed coronary arteries. For example, in March 2023, according to a journal published by Oxford University Press, a UK-based academic publisher of the University of Oxford, the proportion of individuals affected by peripheral artery disease is projected to increase by 50% by 2045. Therefore, the increasing prevalence of cardiovascular diseases is contributing to the expansion of the coronary artery bypass graft market.

Companies operating in the coronary artery bypass graft market are increasingly focusing on technological advancements such as surgical robotic systems to improve precision and reduce procedural invasiveness, ultimately enhancing patient outcomes. In addition, they are exploring the integration of artificial intelligence and minimally invasive techniques to optimize surgical procedures and shorten recovery times. Surgical robotic systems are advanced platforms that assist surgeons in performing minimally invasive operations with greater accuracy and enhanced visualization, typically comprising robotic arms, advanced imaging systems, and a surgeon-controlled console. For instance, in October 2023, SS Innovations International Inc., a US-based manufacturer of surgical and medical instruments, introduced the SSi Mantra surgical robotic system. This system is designed to deliver advanced and cost-effective robotic surgery solutions across multiple specialties, including cardiac procedures. Key benefits include improved surgical precision, shorter recovery periods through minimally invasive approaches, and the incorporation of machine learning to enhance safety and operational efficiency.

In February 2023, Kimal PLC, a UK-based manufacturer of vascular access devices and procedure packs, entered into a partnership with Marizyme, Inc. to secure exclusive distribution rights for DuraGraft in the United Kingdom. Through this collaboration, Kimal and Marizyme aim to combine Marizyme’s advanced vascular graft preservation technology with Kimal’s established distribution network to improve outcomes for patients undergoing coronary artery bypass graft surgery. Marizyme, Inc. is a US-based biomedical company specializing in the development of innovative medical device technologies.

Major companies operating in the coronary artery bypass graft market are CryoLife Inc., Johnson & Johnson Co, Abbott Laboratories, Medtronic plc, Stryker Corporation, Northwell Health, Boston Scientific Corporation, Penn Medicine, Geisinger Health System Co, Terumo Corporation, Edwards Lifesciences Corporation, Main Line Health Inc., Getinge AB, Teleflex Incorporated, W. L. Gore & Associates Inc., Guidant Group, LivaNova PLC, AtriCure Inc., Peter Surgical, Cardiva Medical Inc., Genesee Biomedical Inc., Dextera Surgical Inc., Cardica Inc., Maquet Holding B.V. & Co.KG, Vitalitec International Medizintechnik GmbH.

North America was the largest region in the coronary artery bypass graft market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the coronary artery bypass graft market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the coronary artery bypass graft market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the coronary artery bypass graft market by increasing costs of imported surgical instruments, graft materials, medical devices, and operating room equipment. Hospitals in North America and Europe are most affected due to reliance on imported cardiac surgery tools, while Asia-Pacific faces increased procurement costs. These tariffs are raising procedural expenses. However, they are also encouraging local device manufacturing and strengthening domestic cardiac care supply chains.

The coronary artery bypass graft market research report is one of a series of new reports that provides coronary artery bypass graft market statistics, including coronary artery bypass graft industry global market size, regional shares, competitors with a coronary artery bypass graft market share, detailed coronary artery bypass graft market segments, market trends and opportunities, and any further data you may need to thrive in the coronary artery bypass graft industry. This coronary artery bypass graft market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

A coronary artery bypass graft (CABG) is a surgical procedure performed to treat coronary artery disease. This intervention is used when the coronary arteries that supply blood to the heart become narrowed or blocked, which can lead to conditions such as angina or a heart attack.

The primary types of coronary artery bypass graft procedures include single CABG surgery, double CABG surgery, triple CABG surgery, quadruple CABG surgery, and others. Single coronary artery bypass graft surgery is a surgical approach used in the treatment of coronary heart disease. Both off-pump and on-pump techniques are utilized, and these procedures are carried out by end users such as hospitals, cardiology clinics, research institutes, and other healthcare facilities.

The coronary artery bypass graft market consists of revenues earned by entities by providing services such as bypass grafts, peripheral vascular grafts, hemodialysis access grafts, and endovascular stent grafts. The market value includes the value of related goods sold by the service provider or included within the service offering. The coronary artery bypass graft market also includes sales of forceps, vascular forceps, grasping forceps, needle holders, scissors, and clamps. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.